We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01046539
First Posted: January 12, 2010
Last Update Posted: January 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Alkermes, Inc.
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
This is a single site, double-blind, randomized, placebo-controlled, crossover study to assess the pharmacodynamics (PD) of RDC-0313 coadministered with buprenorphine in 12 healthy, opioid-experienced, non-treatment-seeking subjects.

Condition Intervention Phase
Substance-Related Disorders Drug: RDC-0313 + Buprenorphine Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1 Study to Evaluate the Pharmacodynamics of RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Pharmacodynamics (PD) of study drug [ Time Frame: 24 hour period ]
  • VAS Scores [ Time Frame: 24 Hours period ]
  • Pupuillometry Assessments [ Time Frame: 24 Hour Period ]
  • Subjective Symptoms [ Time Frame: 15 min pre and post nal, 3 hrs post bup admin ]

Secondary Outcome Measures:
  • To determine pharmacokinetics (PK) and evaluate safety and tolerability of study drug [ Time Frame: 24 hour period ]
  • Max plasma concentration [ Time Frame: 24 Hour Period ]
  • Time to maximum plasma concentration [ Time Frame: 24 Hour Period ]
  • Area under the concentration time curve (AUC) [ Time Frame: 24 Hour Period ]
  • Additional PK parameters may be analyzed [ Time Frame: As appropriate ]

Estimated Enrollment: 12
Study Start Date: January 2010
Study Completion Date: July 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: RDC-0313 + Buprenorphine
Cohort 1 (1 and 4 mg) + 8 mg Cohort 2 (dependent on Cohort 1 results)
Drug: RDC-0313 + Buprenorphine
1 and 4 mg (1 dose for each) + 8 mg
Placebo Comparator: Placebo Drug: Placebo
0 mg

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must be capable of understanding and complying with the protocol and has signed the informed consent
  • Must be 18-55 years of age
  • Must have a body mass index of 18.0-30.0 kg/m2 at screening
  • Female subjects must agree to use an acceptable method of contraception from date of consent and until two weeks after the last dose
  • Subjects must be willing not to use alcohol-, tobacco, caffeine-, or xanthine-containing products while resident at inpatient facility
  • Subjects must be an experienced opioid user who meets the following criteria: 1) has used opioids for non-therapeutic purposes (ie, for psychoactive effects) on at least 10 occasions in the past five years; 2) has used opioids at least 2 times in the two years prior to screening; and 3) is not physically dependent on opioids, as assessed by medical history and naloxone challenge performed at screening

Exclusion Criteria:

  • Must not have any current or piror significant hepatic, renal, endocrine, cardiac, nervous, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic disorders.
  • Must not have current or past opioid, alcohol, or other durg dependence (excluding nicotine and caffeine) or showing signs of withdrawal following the naloxone (Narcan) challenge.
  • Please contact site for additional information about other exclusion criteria.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01046539


Locations
United States, California
Langley Porter Psychiatric Hospital
San Francisco, California, United States, 94143
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Alkermes, Inc.
  More Information

Responsible Party: Reese Jones, M.D. / Principal Investigator, Langley Porter Psychiatric Hospital
ClinicalTrials.gov Identifier: NCT01046539     History of Changes
Other Study ID Numbers: ALK33-008
First Submitted: January 8, 2010
First Posted: January 12, 2010
Last Update Posted: January 11, 2017
Last Verified: July 2010

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
ALKS-33
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists